Basil Hamblin, MD
Geriatric Medicine · Point Reyes Station, CANPI 1114095106
Payments from drug & device makers
Across 172 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$543
- Novo Nordisk$360
- Indivior Inc.$309
- Sunovion Pharmaceuticals Inc.$278
- Astellas Pharma US Inc$179
- Pfizer$125
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,11699%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 34 | $543 |
| Novo Nordisk | 20 | $360 |
| Indivior Inc. | 16 | $309 |
| Sunovion Pharmaceuticals Inc. | 18 | $278 |
| Astellas Pharma US Inc | 9 | $179 |
| Pfizer | 6 | $125 |
| Kyowa Kirin, Inc. | 5 | $117 |
| UCB, Inc. | 5 | $117 |
| Novartis | 9 | $116 |
| Nestle Healthcare Nutrition Inc. | 5 | $87 |
| Johnson & Johnson | 5 | $83 |
| Braeburn Inc. | 3 | $81 |
| Sanofi Pasteur Inc. | 5 | $78 |
| AstraZeneca | 3 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Boehringer Ingelheim | 3 | $70 |
| Merck | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Mimedx Group, Inc. | 2 | $49 |
| Argenx US, Inc. | 2 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Eisai Inc. | 2 | $37 |
| Insmed, Inc. | 1 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Biogen | 1 | $15 |
| Gilead | 1 | $12 |
| Circassia Inc. | 1 | $12 |
How this compares
$3,134 in reported general payments places this provider in the 85th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 241 | $143,601 |
| XareltoRivaroxaban | 68 | $35,225 |
| RybelsusSemaglutide | 12 | $32,748 |
| JardianceEmpagliflozin | 64 | $28,173 |
| EntrestoSacubitril/Valsartan | 42 | $20,252 |
| MyrbetriqMirabegron | 21 | $13,297 |
| OzempicSemaglutide | 14 | $12,247 |
| NeuproRotigotine | 13 | $11,509 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 37 | $10,980 |
| Atorvastatin Calcium | 535 | $7,625 |
| PradaxaDabigatran Etexilate Mesylate | 25 | $7,258 |
| Gabapentin | 214 | $6,358 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $6,279 |
| JanuviaSitagliptin Phosphate | 20 | $5,756 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $125 | $146,460262 claims |
| Novo NordiskRybelsus, Ozempic | $360 | $44,99526 claims |
| Boehringer IngelheimJardiance, Pradaxa | $70 | $35,43189 claims |
| Johnson & JohnsonXarelto | $83 | $35,22568 claims |
| NovartisEntresto | $116 | $20,25242 claims |
| AstraZenecaLokelma, Symbicort, Farxiga | $77 | $14,96545 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $13,29721 claims |
| UCB, Inc.Neupro | $117 | $11,50913 claims |
| GSKArexvy | $21 | $10,98037 claims |
| MerckJanuvia | $55 | $5,75620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Point Reyes Station
- Paul AisenSan Diego$15.7M
- Kanagaratnam SivalingamLancaster$2.4M
- Wayne ChenLos Angeles$2M
- Robert FeldmanLaguna Hills$1.9M
- Isabel PereiraFountain Valley$1.2M
- Timothy ParenteauOakland$221K
- Oscar ChienSan Gabriel$208K
- Anna ChangSan Francisco$170K
- Anders NybergSan Diego$163K
- Christopher SalemIrvine$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.